Background: Visfatin, as an adipocytokine, has insulin-mimetic effects including inhibition of hepatic glucose release, augmentation of glucose uptake in adipocytes and myocytes and increase in triglyceride synthesis and its accumulation in pre-adipocytes. However, since the results of this study were not confirmed by subsequent analyses, it was in part retracted. Hence, we aim to evaluate serum visfatin in prediabetes , newly diagnosed type 2 diabetes mellitus subjects and to find correlation of visfatin with BMI, HOMA-IR and HOMA-β) (if any) Methods: 75 prediabetes subjects, 75 newly diagnosed type 2 diabetes mellitus subjects and 75 healthy control subjects (age, gender and body mass index (BMI) matched) were enrolled. BMI, glucose, insulin and visfatin were assessed. Insulin resistance and insulin secretory capacity (measured by homeostasis model assessment: HOMA-IR and HOMA-β) were calculated. Results: Visfatin levels were highly significant in patients with Newly Diagnosed Diabetic compared to controls, whereas significant difference was also found between PDM vs. controls. BMI did not correlate with visfatin in both study groups.Visfatin in prediabetics is not associated with any metabolic parameters i.e. glucose, insulin, HOMA IR and HOMA β. Visfatin concentrations have significant positive association with glucose while significant negative association with HOMA-β in Newly Diagnosed Diabetic subjects. Conclusion: Increased levels of visfatin in prediabetics and Newly Diagnosed Diabetic are not affected by obesity and and insulin resistance.